Daiichi Sankyo and AstraZeneca Receive EU Approval for Datroway in First-Line Metastatic TNBC
TOKYO, July 31, 2026 Daiichi Sankyo and AstraZeneca announced that the European Commission (EC) has approved Datroway® (datopotamab deruxtecan)...
Datroway
Advertisement
AstraZeneca, Daiichi Sankyo Advance Datroway Toward EU Approval
CAMBRIDGE, UK & TOKYO, Japan, June 26, 2026 AstraZeneca and Daiichi Sankyo have moved one step closer to expanding...
Datroway by AstraZeneca Approved as First TROP2 ADC for TNBC
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration...
AstraZeneca Unveils Major ASCO 2026 Cancer and Rare Disease Data
CAMBRIDGE, UK, 22 May 2026 AstraZeneca announced a major scientific showcase at the upcoming ASCO Annual Meeting 2026, highlighting...
AstraZeneca Unveils Landmark Cancer Trial Results at ESMO 2025
Madrid, Spain – October 11, 2025 – AstraZeneca presented groundbreaking clinical trial results from four major Phase III studies...
Advertisement
